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Abstract 
Background: Under competing risks, the commonly used sub-distribution hazard ratio (SHR) 
is not easy to interpret clinically and is valid only under the proportional sub-distribution 
hazard (SDH) assumption. This paper introduces an alternative statistical measure: the 
restricted mean time lost (RMTL). 
Methods: First, the definition and estimation methods of the measures are introduced. 
Second, based on the differences in RMTLs, a basic difference test (Diff) and a supremum 
difference test (sDiff) are constructed. Then, the corresponding sample size estimation 
method is proposed. The statistical properties of the methods and the estimated sample size 
are evaluated using Monte Carlo simulations, and these methods are also applied to two real 
examples. 
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Results: The simulation results show that sDiff performs well and has relatively high test 
efficiency in most situations. Regarding sample size calculation, sDiff exhibits good 
performance in various situations. The methods are illustrated using two examples. 
Conclusions: RMTL can meaningfully summarize treatment effects for clinical decision 
making, which can then be reported with the SDH ratio for competing risks data. The 
proposed sDiff test and the two calculated sample size formulas have wide applicability and 
can be considered in real data analysis and trial design. 
 
KEY WORDS: Competing risks; Hypothesis tests; Proportional sub-distribution hazard 
assumption; Restricted mean time lost 
 
1. Background 
Competing risks arise frequently in many applications in medical studies. In a competing 
risks setting, patients may fail due to multiple causes. The most commonly researched 
endpoint is recorded as the event of interest; other endpoints, whose occurrence may preclude 
the occurrence of the event of interest, are recorded as competing events [1]. When 
competing risks exist, the Kaplan-Meier estimation tends to overestimate the cumulative 
incidence function, which may cause large errors and lead to incorrect conclusions [2, 3]. The 
commonly used measures in the present competing risks data analysis are the cumulative 
incidence function (CIF), sub-distribution hazard (SDH), and cause-specific hazard (CSH) [4, 
5]. CIF curves are used to describe or explore patients’ trend of survival in cases of 
competing risks, and the measures of treatment effect corresponding to the SDH and CSH are 
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the sub-distribution hazard ratio (SHR) and cause-specific hazard ratio (CHR), respectively. 
Lau et al. [3] pointed out that the CHR regards competing events as right censored and is 
more suitable for epidemiologic studies, while the SHR is good at estimating risk factors and 
treatment effects, which makes it more applicable in clinical studies. Thus, the SHR is given 
as the commonly used descriptive index for the comparison of CIFs between groups. 
However, the SHR also has limitations in some applications: i) the most commonly used 
method, the Gray test [6], needs to satisfy the proportional SDH assumption [7]; ii) normally, 
the descriptive statistic used for competing risks data is the CIF curve; however, the statistical 
inference is the Gray test based on the SDH; thus, the statistical description and statistical 
inference do not match exactly; iii) when the SHR is used to summarize the treatment effect, 
the test framework contains only an SHR of the treatment group vs. the control group instead 
of the SDH for each group. Without baseline (control group) information, the SHR may be a 
relatively abstract concept for patients [8, 9]; iv) the estimation of the SDH is based on 
conditional probability, so that the SHR does not reflect the risk ratio of two groups, which 
complicates the interpretation of survival outcomes [10]. 
 Based on the above limitations of the SHR, the median time can reflect the effect of 
survival, but only on a single time point, which is not a meaningful way to summarize the 
effect on patients over a time period. Calkins et al. [11] referred to the concept of the 
restricted mean survival time under competing risks (RMSTc), which is based on the 
restricted mean survival time (RMST) [12, 13] spent in a state free of composite events. 
However, the simple use of composite endpoints may not have clinical meaning [14]. In 
addition, the RMSTc causes the loss of accuracy regarding the event of interest, and the result 
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can be simplified to the RMST based on the single endpoint by taking all events as one 
composite event. 
Anderson [15] defined the number of life years lost under competing risks settings and 
proposed a regression model based on pseudovalue observations. Zhao et al. [16] introduced 
the restricted mean time lost (RMTL), which corresponds to the area under the CIF curve of 
the event of interest and represents the average of the lost time for the event of interest within 
a specific restricted period of time. 
This paper develops statistical methods based on the RMTL that can avoid the limitations 
of the SHR and RMSTc. The paper is organized as follows. Section 2 presents the definition 
and estimation of measures based on the hazard, the RMTL, and the corresponding 
hypothesis tests and sample size formulas. In Section 3, we conduct simulation studies to 
assess the impact of the proposed tests. Two examples are used to illustrate the proposed 
methods in Section 4. Section 5 provides a discussion of our research. 
 
2. Methods 
Assume a randomized study with n patients in two groups (k=1,2). The time-to-event and 
censoring times are denoted by , 1,2,...,iT t i n= =  and C, respectively. For simplicity, we 
assume that C is independent of T. τ  is the truncation time point, also called the cut-off 
time point. Without loss of generality, two endpoints are assumed in this research: one event 
of interest (j=1) and one competing event (j=2). Let 1( )I t  and 2 ( )I t  be the CIFs for the 
event of interest and competing event, respectively. Based on the nonparametric maximum 
likelihood estimation of the CIF, the estimate of CIF ( )jI t  is 1ˆˆ ( ) ( ) ( )
i
j ij i i
t t
I t d n S t
−
≤
= , 
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where ijd  is the number of events of type j that occur at time ti, the number of individuals at 
risk at ti is denoted by ni, and ˆ( )S t  is the Kaplan-Meier estimate when all events (both j=1 
and j=2) are considered. 
2.1 Descriptive Analysis 
2.1.1 Existing Measure Based on the CSH and SDH 
Both the CSH and the SDH are hazard-related measures. Under competing risks, the CSH of 
an event of interest is defined as 
0
( , 1| )( ) lim ,CSH t
P t T t t j T tt
t
λ
Δ →
≤ < + Δ = ≥
=
Δ
                             (1) 
which indicates the patients’ hazard of the event of interest at t without any prior event. The 
corresponding descriptive measure CHR is the ratio of the CSHs of two groups. 
The SDH of an event of interest is given by 
0
( , 1| ( 1))( ) lim ,SDH t
P t T t t j T t T t jt
t
λ
Δ →
≤ < + Δ = > ∪ < ∩ ≠
=
Δ
                (2) 
which describes the patients’ hazard of the event of interest at t only without previously 
having experienced the event of interest. The corresponding descriptive measure SHR is the 
ratio of the SDHs of two groups. 
In formulas (1) and (2), the main difference between the CSH and SDH is the number of 
individuals at risk. For the CSH, the number at risk at t includes only patients who do not 
experience any type of event, while the number at risk of the SDH includes patients who do 
not experience the event of interest while still including patients who have experienced 
competing events. 
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2.1.2 Alternative Measure Based on the RMTL 
The RMTL of the event of interest is defined as 10RMTL ( )I t dt
τ
=   [15, 16]. Then, based on 
the CIF estimation of the event of interest, 1ˆ( )I t , the estimate of the RMTL is given by 
  10 ˆRMTL ( ) ,I t dt
τ
=                                                   (3) 
and the estimated variance in RMTL is 
   2
1 10 0
2 2
RMTL 10
ˆ ˆ(RMTL ) (RMTL) 2 ( ) [ ( ) ]ˆvar 2 ( ) ,E E tI t dt I t dtI t dt τ τττ= − = −−           (4) 
where  2(RMTL )E  is estimated by 
2 2 2(RMTL ) [( ) | ]Pr( ) [( ) | )]Pr( )E E T T T E T T Tτ τ τ τ τ τ= − ≤ ≤ + − > >  
2
1 1 10 0 0
                       ( ) ( ) 0 2 ( ) 2 ( ) ,u f u du I u du uI u duτ τ ττ τ= − + = −    
and f1(t) is the density function of I1(t). 
The descriptive measure of the RMTL is the RMTL difference between two groups. 
From formula (3), the effect size of the difference in the RMTLs (RMTLd) is related to the 
difference between the two areas under the CIF curves. 
 
2.2 Hypothesis Test Procedures 
2.2.1 Existing Test Procedures Based on the CSH and SDH 
The log-rank test can be directly used as the test corresponding to the CSH [17]. 
 The most commonly used test for the SDH is the Gray test (Gray) [6], the test statistic of 
which is defined as 
(1) (2)
0
( ){ ( ) ( )} ,k k SDH SDHz t t t dt
τ
ϖ λ λ= −  
where ( ) ( )kSDH tλ  is the estimate of the SDH for group k. The weight function is defined as 
ˆ1 ( )( ) ˆ () )(
k
k
k
k
I tn t
S
t
t
ϖ
− −
=
−
, ( )kn t  is the number of individuals at risk at time t in group k, 
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ˆ ( )kI t−  is the left-hand limit of the CIF for the event of interest in group k, and ˆ ( )kS t−  is the 
left-hand limit of the probability of being free of any event in group k, as estimated by the 
Kaplan-Meier method. 
 
2.2.2.2 New Tests Based on the RMTLd 
Basic Difference Test 
Assuming that Δ  is the RMTLd between two groups, then the estimates of Δ , Δˆ , are 
12 110
ˆ ˆ ˆ[ ( ) ( )]I t I t dtτΔ = − , where 1ˆ ( )kI t  is the CIF estimate for the event of interest in group k. 
Thus, we present a basic test procedure based on the RMTLd. Under the null hypothesis 
0 : 0,H Δ = the basic difference test (Diff) statistic is given by 

 ~ (0,1),var( )
Z NΔ=
Δ
 and 
the estimate variance var( )Δ  is derived by the delta method; that is, 

1 1 2 2var( ) var varn nΔ = + ,                                           (5) 
where 21 10 010 ˆ ˆ2 ( ) [ ( ) ]ˆvar 2 ( ) k kk k tI t dt I t dtI t dt
τ ττ
τ −= −    according to formula (3), and nk is the 
sample size in the kth group. 
 
Supremum Difference Test 
We refer to the supremum difference test (sDiff) statistics [18] based on the RMTLd. The test 
statistic is given by ˆ ˆsup{ ( ) , } / ( )r rSQ t t τ σ τ= Δ ≤ , where ˆ ( )rtΔ  is calculated by 
12 11 1 1 2
ˆ ˆ ˆ( ) [ ( ) ( )]( ), , ,..., .
i r
r i i i i r
t t
t I t I t t t t t t τ+
≤
Δ = − − =                            (6) 
The standard error of ˆ ( )rtΔ  is solved by 
2 2
1 12 11
|
ˆ ˆ ˆ ˆ( ) ( ) { [ ( )] [ ( )]}
i
i i i i
i t
t t V I t V I t
τ
σ τ +
<
= − +  
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{ }1/21 ' 1 ' 12 11 12 ' 11 '
'| ,
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ             2 ( )( ) { [ ( )] [ ( )]}{ [ ( )] [ ( )]}
i i
i i i i i i i i
i i t t
t t t t V I t V I t V I t V I t
τ
ρ + +
′< <
+ − − × + +  
based on Aalen’s variance [19] of the CIF estimator, where ρ  is the correlation coefficient 
between 12 11ˆ ˆ( ) ( )i iI t I t− , and 12 ' 11 'ˆ ˆ( ) ( )i iI t I t− , where 'i i≠ . ρ  is difficult to estimate 
because it involves the assumption of an unknown underlying CIF distribution of the actual 
data. Lyu et al. [20] found that when 0.50ρ = , the test statistic does not inflate the type I 
error rate and maintains high power. Hence, we fixed ρ  at an acceptable value of 0.5 in this 
article. 
 Under the null hypothesis, the distribution of SQ  can be approximated by the 
distribution of sup{ ( ) , 1}0M x x≤ ≤ , where M is a standard Brownian motion process. 
According to Billingsley [21], the probability distribution of sup ( )M t  is given by 
2 2 2[ (2 1) /8 ]
0
4 ( 1)[sup ( ) ] 1  .2 1
a
a x
a
P M t x e
a
π
π
∞
− +
=
−
> = −
+
                           (7) 
Assuming that formula (7) converges when a → m [22], then m is solved as 
2 1 1max log ,12
xm
π πε
   
= −     
, where     refers to the minimum positive integer of this 
value, and ε  is the permissible error for estimating [sup ( ) ].P M t x>  
 
2.3 The Sample Size Formula Based on the RMTLd 
Under competing risks, the use of Gray is limited by the proportional SDH assumption. 
Hence, the corresponding sample size formula is not always available. In addition, the 
estimated Gray sample size (based on the Gray) depends on the incidence of the event of 
interest; that is, a large deviation between the actual incidence and the assumed incidence 
results in a broad range of estimated sample sizes. This paper does not discuss the sample 
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size formula for the RMSTc (which can be estimated by the method based on the single 
endpoint), as our focus is on the event of interest. The sample size formulas based on Diff and 
sDiff are proposed in the following section. 
2.3.1 Method Based on the Basic Difference Test 
According to Diff, as shown in Section 2.2.2, the following hypotheses are considered: 
0 1: 0;   : 0.H HΔ = Δ ≠  The test statistic under the null hypothesis 

 ~ (0,1)( )
Z N
σ
Δ
=
Δ
 is 
rejected at the approximate α  level of significance if 

 /2( )
zα
σ
Δ
>
Δ
. We write the 
expression 11 2 (1 2)z α α−− = Φ − , where Φ  is the standard normal distribution. Then, under 
the alternative hypothesis with a desired power of 1 β− , the sample size can be obtained by 
solving 1 2 1 1 2 1 1 2 11 ( | ) ( | ) ( | ).P Z z H P Z z H P Z z Hα α αβ − − −− = > = > + < −  
By symmetry of the normal distribution, 1 2 1( | )P Z z Hα−>  and 1 2 1( | )P Z z Hα−< −  are 
equal. Thus, we obtain 1 21 ( )z αβ σ−
Δ
− Φ − + , i.e., 21 1 2( ) .z zβ α σ− −+ = Δ  
According to formula (5), we have 
2 2 2 2
2 11 2 1 2
1 2
(1 ) ( )r r
n n n n
σ σ σ σ
σ −= + = + × + × , where 2
1
n r
n
= . 
Thus, the total required sample size is 
2
1 1 2
2 2 1 2
1 2
( )(1 ) ( )
z z
n r
r
β α
σ σ
− −
−
+
= +
Δ +
. 
 
2.3.2 Method Based on the Supremum Difference Test 
In the sample size calculation of the supremum test, the main purpose is to obtain ξ  in 
function n nξ= ⋅  , where n  is the calculated sample size based on Diff. 
As with 0 1: 0;   : 0,H HΔ = Δ ≠ , we assume that 0ηΔ = ≠  under the alternative 
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hypothesis. Then, we write the expression  
( ) ( ( ) ( )
ˆ ( ) ) ,ˆ ( )U t M u t u t
t η
σ τ
= =
Δ
+  
where ( )M ⋅  is a standard Brownian motion process and ( )u t is a time function. Then, U(t) 
is a standard Brownian motion process that deviates with a mean of η . Here, we assume 
Rη λ=  with a fixed effect size λ , where ( ),R nR τ=  and R(t) is the probability that the 
event of interest happened before t. Then, the relation of R and η  is given by 
2
2 .R
η
λ=
                                                             (8) 
 Assume that 1 /2V α− is the critical value of the supremum value of the standard Brownian 
motion process, i.e., 
[ ] [ ] [ ]1 /2 1 /2 1 /20,10,1 0,1
{sup ( ) } {sup ( ) } { inf ( ) } .
uu u
P M u V P M u V P M u Vα α α α− − −
∈∈ ∈
> = > + < − =      (9) 
By the symmetry of Brownian motion, both probabilities, 
[ ] 1 /20,1
{sup ( ) }
u
P M u V α−
∈
>  and 
[ ] 1 /20,1{ inf ( ) }uP M u V α−∈ < − , are equal. Hence, we only need to consider the calculation of 
[ ] 1 /20,1
{sup ( ) }
u
P M u V α−
∈
>  here. According to the joint distribution of 
[ ]0,1
sup ( )
u
M uη
∈
 and (1)Mη
[22], ( )Mη ⋅  is the Brownian motion with a mean of η . Eng and Kosorok [23] obtained the 
following function after integration: 
[ ]
1 /22
0,1
{sup ( ) } ( ) e ( )V
u
P M u x x xαηη η η−
∈
> = Φ − + Φ + . 
Thus, the sample size needed to achieve a desired power of 1 β−  with a two-sided type I 
error of α can be obtained by 
1 /22
1 /2 1 /2( ) e ( ) 1 ,TV Vαηα αη η β−− −Φ − + Φ + = −                                (10) 
where 1-Φ = Φ  and Φ  is the standard normal distribution. 
Under the alternative hypothesis, we obtain the limiting distribution of ( )nU τ  as 
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(1)Mη , which is a normal deviation with mean η  and variance 1. With a critical value 
1 /2Z α− , we solve for η  in the following expression: 1 /2( ) 1 ,Z α η β−Φ − = −  that is, 
1 /2 1 .Z Zα βη − −= +  Hence, we obtain 
2
1 /2 1
2
( ) .Z ZR α βλ
− −
+
=
                                                 (11) 
Because formulas (8) and (11) have the same effect size λ , the denominators cancel, and the 
ratio becomes 
2
2
R
R
η ξ
η
= =  , where only η  remains to be solved. 
First, we need to estimate the critical value V  in formula (9). From the cumulative 
probability distribution [21] 
2 2 2[ (2 1) /8 ]
0
4 ( 1)[sup ( ) ]  ,2 1
a
a x
a
P M t x e
a
π
π
∞
− +
=
−≤ =
+
  
let 2 2 2[ (2 1) /8 ]
0
4 ( 1)1 ,2 1
a
a x
a
V e
a
π
π
∞
− +
=
−
= −
+
  and assume that V converges when a → m. Then, m is 
solved as 2 1 1max log ,12
xm
π πε
   
= −     
 [23], where     refers to the minimum 
positive integer of this value, and ε  represents the residuals. Finally, assume a function, 
2( ) ( ) ( )uxY x u x e u x= Φ − + Φ + , with a derivative function of 
2 2'( ) ( ) ( ) 2 ( )ux uxY x u x e u x ue u xϕ ϕ= − − + + + Φ + . Use the Newton-Raphson iteration to solve 
for η  in formula (10), let (1 ) ( )'( )i
Y x
Y x
β
ο
− −
= , and iterate the cycle until ο ε≤ ; the estimate 
η  is given by 
i
η η ο= + . 
 
3. Results 
3.1 Hypothesis Test Procedures 
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3.1.1 Simulation Design 
To compare the performance of the above tests, Monte Carlo simulations were carried out to 
study the type I error and the statistical power under a variety of situations. The following 
procedures were performed to test the hypotheses: Gray, Diff, and sDiff. The performance of 
these tests was evaluated by using 6 alternative scenarios (Figure 1): (A) two groups with no 
difference (the comparison for type I error); (B) two groups with a proportional SDH 
difference; (C) two groups with a non-proportional SDH difference; (D) an early difference in 
the CIFs; (E) CIFs with a late difference; (F) two CIFs with a cross difference. 
Let 1τ  and 2τ  be the last event of interest time in the two groups. Here, we considered 
a commonly used option, the minimum of the last event in the time of interest in two groups 
( 1 2min( , )τ τ τ= ), as τ . The event of interest and the competing event were generated from 
CIFs with piecewise Weibull distributions. The specific parameter settings are presented in 
Web Table A1. The distribution of events was based on the binomial distribution 1) ( ,B N p , 
where N represents the sample size of each group and p1 is the maximum cumulative 
incidence of events of interest, which is set as 1 1( ) 0.7p I= ∞ = . The censored times C in the 
two groups were generated from uniform distributions. Then, each individual was assigned an 
observed time t=min(T, C) and the event indicator δ=0[T>C]. By changing the distribution 
parameters of C, both groups were set to have the same censoring rates of approximately 0, 
15%, 30% and 45%. We also considered equal group sizes (n1=n2=50, 100, 150) and unequal 
group sizes (n1=50, n2=100; n1=50, n2=150; n1=50, n2=200). All simulations were performed 
using 5000 iterations. The nominal significance level of each method was fixed at the 
conventional level of 0.05. 
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 3.1.2 Simulation Results 
As Table 1 shows, the type I error rates for Diff are stable under 0 censoring but gradually 
inflate with increasing censoring rates, which represent the most radical test. As the type I 
error rates of Diff are inflated, this test is not included in the comparison of test power. 
Compared to Diff, Gray is steadier. The type I error rates of sDiff are relatively conservative 
for light censoring but increase with increasing censoring rates. 
The power results are shown in Table 1. When two CIF curves have a proportional SDH 
(Figure 1B), the powers of all the tests increase with increasing sample size but decline with 
increasing censoring rates. Gray demonstrates the optimal power in this situation, followed 
by sDiff. For the non-proportional SDH difference (Figure 1C), sDiff is the most powerful 
test, while Gray has the lowest power in this situation. For the early difference in the CIF 
curves (Figure 1D), with increasing censoring rates, sDiff becomes much more powerful, and 
Gray exhibits the lowest power in this situation. When considering the late difference in the 
CIF curves (Figure 1E), the powers of all tests decline with increasing censoring rates. In this 
situation, Gray is more powerful, followed by sDiff. In the case of a cross difference in the 
CIF curves (Figure 1F), Gray has the lowest power. With increasing censoring rates, sDiff is 
much more powerful than Gray. 
Note that in situation C (non-proportional SDH), situation D (early difference), and 
situation F (cross difference), all tests exhibit gradually increasing power with increasing 
censoring rates. This result occurs because the two CIF curves are not convergent in the later 
period but diverge with the increased censoring, which makes the increased difference 
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between the two CIF curves proportional. 
To summarize the simulation results, we applied the analysis of variance (ANOVA) 
technique [24] to evaluate the type I error and power. For type I error, the absolute small and 
close-to-zero estimates indicate that rates are close to 0.05. For power, good performance is 
indicated by large estimated values (see details in Appendix A). Table 2 shows that sDiff 
corrects the inflated type I error of Diff when censoring occurs. In Table 3, sDiff is slightly 
lower than Gray when there is a proportional SDH (situation B), and when there is a late 
difference (situation E), the difference between Gray and sDiff is approximately only 2.242%, 
whereas the powers of sDiff are much higher than those of Gray in other situations. 
Considering all situations, combinations of sample sizes, and censoring rates, sDiff performs 
better in most situations. 
 
3.2 Calculations of Sample Size 
3.2.1 Simulation Design 
A simulation study was also performed to evaluate the proposed sample size formula. Two 
scenarios were considered (Figure 1 B-C): (B) two groups with a proportional SDH 
difference and (C) two groups with a non-proportional SDH difference. Both scenarios were 
examined under four scenarios with either 0.05 or 0.01 for the two-sided type I error and with 
either 0.8 or 0.9 as the power. The follow-up time, τ , which is also the truncation time point, 
was set as the minimum of the last observed time of the pilot study for two groups. Assume 
two groups with an equal sample size, i.e., r=1. Then, based on situation B and situation C, 
the necessary parameters were estimated by simulation, and finally, we obtained the 
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calculated sample size with the given parameters. In addition, Monte Carlo simulations were 
used to examine the observed power. The simulations were performed using 1000 
replications. 
 
3.2.2 Simulation Results 
As shown in Table 4, the calculated sample size of all the tests increases with a decreasing 
type I error rate and with an increasing target power. When the CIFs satisfy the proportional 
SDH assumption (situation B, Figure 1B), the calculated sample sizes of Gray, Diff and sDiff 
are close to each other, with Diff having the highest observed power. In this situation, Gray 
and sDiff have a similar observed power, which is close to the target power. When there is a 
non-proportional SDH (situation C, Figure 1C), the calculated sample sizes of Gray are much 
higher than those of Diff and sDiff, and sDiff has a relatively high observed power. In 
addition, the observed powers of Gray do not reach the target power in this situation. 
In addition, the comparison of power for Gray, Diff and sDiff with a fixed sample size 
(calculated by sDiff) is shown in Web Table A2. The results show that the power under 
situation B for Diff is larger than that for Gray and sDiff, but the three tests have similar 
power. However, in situation C, the power of Gray is much lower than that of Diff and sDiff. 
As the type I error rates of Diff are inflated with censoring, the corresponding sample size 
formula is considered unstable. In general, when the CIFs satisfy the proportional SDH 
assumption, both Gray and sDiff can be considered; when the SDH is non-proportional, sDiff 
is considered more adaptive. 
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4. Applications 
4.1 Example 1: Bone Marrow Transplantation Data 
The data used to evaluate the effect of T-cell depletion on bone marrow transplantation [25] 
came from 408 patients divided into a T-cell depleted group (Yes) with 354 cases and a T-cell 
not depleted group (No) with 54 cases. The censoring rates for the two groups were 
approximately 41% and 28%, respectively. The study included two types of events: death 
from treatment-related causes, which was defined as the event of interest, and relapse, which 
was set as a competing event. At the end of follow-up, 161 patients (146 from the Yes group 
and 15 from the No group) experienced an event of interest, and 87 patients (70 from the Yes 
group and 17 from the No group) experienced competing events. A test of the proportional 
SDH assumption yielded a result of P=0.264. 
 The descriptive statistics and the hypothesis test results for the examples are shown in 
Table 5. In the hazard-related measures, the CHR and SHR showed that the ratios of the Yes 
group vs. the No group were 0.86 (0.59, 1.25) and 0.60 (0.36, 1.00), respectively. However, 
the log-rank test, which is based on the CHR, showed no significant differences (P=0.053), 
while Gray based on the SHR indicated that there were significant differences between the 
two groups (P=0.049). In addition, we could not obtain the estimated CSH or SDH for either 
group, which led to a lack of descriptive information for either group; only a CHR or an SHR 
could be obtained. This outcome led to difficulty in clinical interpretation. 
 For the composite endpoint, the RMSTc showed that the mean survival time of the 
patients in the Yes group was 1.83 (-5.03, 8.69) months longer than that of the patients in the 
No group within the truncation time point of 41.8 months, and there were no significant 
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differences (P=0.601). Additionally, the RMSTc could not provide information regarding 
treatment-related death. 
 Let τ =41.8 months; Table 5 shows that the RMTL of treatment-related death in the Yes 
group was 9.57 (5.18, 13.96) months, which corresponds to the area under the CIF curve, i.e., 
S2 in Figure 2A. In the No group, the RMTL corresponds to the area under the CIF curve, i.e., 
S1+S2=15.49 (13.53, 17.45) months. Hence, the difference in RMTL between the two groups 
has an area of S1, which means that the patients in the Yes group took 5.92 (1.11, 10.72) 
months longer to succumb to treatment-related death. According to Table 5, the RMTL-based 
tests (Diff and sDiff) showed significance at the conventional level of 0.05. 
As shown in Figure 2B, a selection of different τ  values led to a difference in the 
calculated sample size for Diff and sDiff: the calculated sample size increased with increasing 
τ  and became steady after 20 months. The calculated sample sizes at τ = 41.8 months were 
280 and 298 for Diff and sDiff, respectively, both of which were close to the sample size 
calculated by Gray (n=300). 
 
4.2 Example 2: Lymphocytic Leukemia Data 
A previous study compared the effects of radiotherapy in the treatment of patients with 
lymphocytic leukemia (LL). A total of 1400 patients were randomly extracted from the 
Surveillance, Epidemiology, End Results (SEER) Program. Among these patients, two groups 
were included: the no radiotherapy group (No RT) consisted of 1318 cases, and the 
radiotherapy group consisted of 82 cases. The censoring rates in the two groups were 
approximately 3% and 44%, respectively. During the follow-up, death from LL was set as the 
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event of interest; death from other causes was recorded as a competing risk. At the end of the 
research, 364 patients (333 from the No RT group and 31 from the RT group) had died from 
LL, and 467 patients (452 from the No RT group and 15 from the RT group) had died from 
other causes. The corresponding test indicated a severe violation of the proportional SDH 
assumption (P=0.006). 
 Regarding the hazard-related indexes, Table 5 shows that the No RT group had a lower 
hazard ratio than the RT group (CHR=1.14 (0.78,1.65); SHR=1.45 (0.98, 2.14)). However, in 
this example, the SHR varied with time (P=0.006) instead of being constant. Therefore, the 
CHR and SHR may not be available for this example. 
 When considering the composite endpoint, the RMSTc showed that the mean survival 
time of the RT patients was 0.66 (-1.13,2.28) years longer than that of the No RT patients 
within the truncation time point of 15.3 years (Table 5), which reflected the overall survival 
but could not reflect the survival rates of patients who died of LL. 
 Let τ = 15.3 years; Table 5 shows that the RMTL of LL-related death in the RT group 
was 4.68 (3.34, 6.03) years, which is equal to the area of S1+S2 in Figure 2C and 
corresponds to the area under the CIF curve. In the No RT group, the RMTL was S2=2.96 
(2.69, 3.24) years. The difference in the RMTL between the two groups was S1=1.72 (0.35, 
3.09) years, which is the delay time until the patients in the No RT group succumbed from 
LL-related death. As shown in Table 5, for all test procedures, only Diff and sDiff, which 
were based on the RMTL, showed significance at the conventional level of 0.05. 
As Figure 2D shows, with increasing τ , the calculated sample sizes showed a trend of 
decreasing first and then increasing, and they reached the smallest estimation of sample size 
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at approximately 7 years, which was much less than the results found with Gray (n=886). The 
calculated sample sizes at τ = 15.3 years were 344 and 364 for Diff and sDiff, respectively. 
 
5. Discussion 
When dealing with competing risks datasets, the SHR is often used as a typical descriptive 
method with the test procedures. However, because the SHR lacks baseline information (a 
control group) and does not directly reflect the risk ratio of the two groups, it may complicate 
the interpretation of the survival outcome and may be a relatively abstract concept for 
patients. The RMSTc can directly describe patient survival and does not depend on the 
proportional SDH assumption, but the simple use of composite endpoints does not always 
have clinical meaning and degrades the accuracy of patient information [14]. Conversely, the 
RMTL can avoid some limitations of the above methods. Moreover, the relationship between 
the RMTL and RMSTc can be derived as 1 2 cRMTL RMTL RMTL RMSTj τ+ + + + = , 
where RMTLj means the area under the CIF curves for cause j. As RMTLj is interpreted as 
the average survival time lost due to cause j within τ , the RMTL can be observed from the 
CIF curves directly, while the SHR cannot directly reflect the CIF curves. In addition, Gray, 
which corresponds to the SHR, needs to satisfy the proportional SDH assumption, while the 
RMTL-related tests do not. From the simulation results of the hypothesis testing procedures, 
sDiff, which is based on the RMTLd, corrects the severe skewness of Diff under high 
censoring and has improved power under various scenarios compared to Gray. In general, 
sDiff maintains good performance compared to Gray and Diff. In addition, this paper also 
contains sample size formulas based on the RMTLd. When the proportional SDH assumption 
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is satisfied, the calculated sample sizes of Diff and sDiff are close to that of Gray, while Diff 
still has the highest power. Because the type I error rates of Diff are inflated with censoring, 
we still suggest that Gray and sDiff be used in this situation; however, when the SDH is 
non-proportional, the sample sizes estimated by Gray are much larger than those estimated by 
Diff and sDiff with the lowest observed power. Hence, in this situation, sDiff seems more 
adaptable for use. 
The sample sizes calculated in the examples (Figure 2B, D) suggest that different choices 
of τ  may have a large influence on the calculation of the sample size. In example 1, the 
calculated sample size increases with increasing τ  and is similar to the sample size 
estimated by Gray after 20 months (Figure 2B), while in example 2, the calculated sample 
sizes show a trend of decreasing first and then increasing (Figure 2D). Hence, it is important 
to choose an appropriate τ  for the calculated sample size of Diff and sDiff. In practical 
research, τ is always determined as the follow-up time in the study design. If all patients in 
one of the groups experience an endpoint during the follow-up period, then the study is 
stopped, and this time point is determined as the final analysis of the study, i.e., τ ; otherwise, 
if patients in either group do not have a completely observed endpoint until the end of the 
follow-up period, then the designed follow-up period is regarded as the truncation time point. 
In this paper, the calculated sample sizes in simulations are based on the minimum time of the 
last observation of the event of interest in the two groups as τ . The issue of how to define 
an appropriate τ  in a specific research context will be considered in a future study. 
 
6. Conclusions 
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The RMTL can meaningfully summarize treatment effects for clinical decision making, 
which can be reported with the SDH ratio for competing risks data. The proposed sDiff test is 
robust and can be considered for statistical inference in real data analysis; the two proposed 
calculated sample size formulas have wide applicability and can also be applied to real trial 
designs. 
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Table 1 Type I error rates and powers of the test procedures 
n1, n2 Cen (%) 
Situation A Situation B Situation C Situation D Situation E Situation F 
Gray Diff sDiff Gray Diff sDiff Gray Diff sDiff Gray Diff sDiff Gray Diff sDiff Gray Diff sDiff 
50,50 0 0.046  0.053  0.025 0.795 0.813 0.689 0.128 0.383 0.109 0.076 0.258 0.155 0.251 0.228 0.182 0.053 0.190 0.153 
 15 0.049  0.063  0.033 0.784 0.799 0.678 0.200 0.438 0.161 0.101 0.307 0.185 0.207 0.171 0.134 0.070 0.234 0.192 
 30 0.049  0.074  0.043 0.707 0.734 0.639 0.302 0.555 0.329 0.142 0.381 0.247 0.129 0.100 0.076 0.105 0.328 0.288 
 45 0.051  0.078  0.052 0.635 0.666 0.573 0.477 0.761 0.671 0.214 0.549 0.427 0.066 0.068 0.059 0.196 0.611 0.583 
100,100 0 0.056  0.056  0.032 0.976 0.982 0.952 0.189 0.541 0.238 0.112 0.370 0.255 0.404 0.437 0.393 0.070 0.247 0.253 
 15 0.052  0.066  0.032 0.974 0.980 0.946 0.310 0.599 0.288 0.156 0.423 0.289 0.364 0.357 0.307 0.107 0.289 0.309 
 30 0.052  0.078  0.043 0.947 0.960 0.922 0.493 0.735 0.509 0.237 0.513 0.375 0.222 0.182 0.153 0.171 0.386 0.432 
 45 0.050  0.082  0.051 0.907 0.926 0.885 0.744 0.931 0.880 0.375 0.711 0.632 0.103 0.100 0.086 0.332 0.679 0.782 
150,150 0 0.052  0.055  0.028 0.997 0.999 0.994 0.261 0.669 0.371 0.136 0.483 0.359 0.514 0.611 0.567 0.078 0.315 0.429 
 15 0.054  0.065  0.032 0.998 0.998 0.994 0.432 0.728 0.433 0.210 0.524 0.396 0.493 0.516 0.463 0.131 0.361 0.482 
 30 0.052  0.072  0.040 0.994 0.995 0.988 0.660 0.851 0.682 0.330 0.610 0.498 0.298 0.259 0.223 0.237 0.472 0.627 
 45 0.050  0.077  0.042 0.984 0.986 0.978 0.902 0.983 0.961 0.510 0.807 0.801 0.122 0.111 0.096 0.456 0.764 0.935 
50,100 0 0.055  0.060  0.034 0.882 0.910 0.824 0.119 0.457 0.177 0.111 0.285 0.181 0.283 0.314 0.288 0.038 0.243 0.245 
 15 0.058  0.071  0.041 0.877 0.905 0.824 0.190 0.519 0.233 0.152 0.328 0.216 0.271 0.262 0.236 0.058 0.304 0.294 
 30 0.054  0.078  0.047 0.829 0.863 0.793 0.303 0.640 0.425 0.216 0.405 0.277 0.172 0.142 0.125 0.096 0.411 0.394 
 45 0.050  0.079  0.050 0.768 0.808 0.748 0.521 0.865 0.783 0.320 0.588 0.488 0.085 0.081 0.074 0.188 0.663 0.668 
50,150 0 0.050  0.056  0.029 0.908 0.931 0.860 0.114 0.509 0.203 0.125 0.292 0.189 0.297 0.350 0.333 0.033 0.288 0.315 
 15 0.054  0.069  0.032 0.905 0.931 0.864 0.192 0.566 0.261 0.175 0.332 0.219 0.300 0.298 0.281 0.049 0.349 0.365 
 30 0.055  0.078  0.045 0.869 0.900 0.846 0.313 0.701 0.498 0.252 0.415 0.291 0.202 0.164 0.156 0.085 0.470 0.475 
 45 0.049  0.078  0.049 0.812 0.856 0.804 0.558 0.899 0.842 0.378 0.605 0.522 0.088 0.084 0.082 0.186 0.713 0.743 
50,200 0 0.053  0.059  0.035 0.917 0.947 0.881 0.111 0.536 0.212 0.133 0.302 0.200 0.301 0.377 0.365 0.029 0.309 0.358 
 15 0.056  0.071  0.039 0.917 0.944 0.883 0.182 0.589 0.279 0.189 0.346 0.231 0.313 0.329 0.324 0.047 0.377 0.411 
 30 0.054  0.080  0.050 0.887 0.917 0.872 0.312 0.715 0.520 0.276 0.426 0.315 0.222 0.186 0.181 0.084 0.501 0.519 
 45 0.051  0.082  0.052 0.841 0.877 0.833 0.566 0.917 0.866 0.409 0.608 0.543 0.095 0.098 0.094 0.181 0.747 0.780 
Cen: censoring rate for each group. 
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Table 2 Average deviations (%) from the nominal 5% level of the tests (TEST) adjusted 
using ANOVA 
 Gray    Diff sDiff 
Model 1 50,50 -0.100 1.735 -1.160 
n1, n2 100,100 0.230 2.035 -1.065 
 150,150 0.185 1.715 -1.435 
 50,100 0.415 2.205 -0.710 
 50,150 0.175 2.010 -1.135 
 50,200 0.360 2.295 -0.595 
Model 2 0 0.193 0.657 -1.933 
cen 15% 0.373 1.733 -1.533 
 30% 0.260 2.673 -0.527 
 45% 0.017 2.933 -0.073 
Model 4 0.211 1.999 -1.017 
cen: censoring rate. 
 
 
Table 3 Average rejection rates for the tests (TEST) adjusted using ANOVA 
 Gray Diff sDiff 
Model 1 50,50 23.184 37.869 27.650 
n1, n2 100,100 35.978 51.732 44.426 
 150,150 43.716 60.222 56.389 
 50,100 27.389 44.954 36.473 
 50,150 29.203 48.274 40.747 
 50,200 30.059 50.240 43.338 
Model 2 0 31.467 48.584 39.116 
cen 15% 34.505 50.335 40.591 
 30% 36.983 53.062 45.576 
 45% 43.398 63.546 60.732 
Model 3 B 87.956 90.108 84.463 
sit C 35.752 67.038 45.554 
 D 22.228 45.288 34.544 
 E 24.175 24.266 21.993 
 F 12.831 42.710 45.965 
Model 4 36.588 53.882 46.504 
cen: censoring rate; 
sit: simulated situation. 
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Table 4 Simulation results for sample size 
α  β Situation Gray Diff sDiff 
n Power n Power n Power 
0.05 0.8 B 102 0.804 108 0.852 116 0.790 
  C 606 0.767 208 0.862 220 0.886 
0.05 0.9 B 136 0.894 144 0.925 152 0.898 
  C 810 0.882 278 0.919 294 0.965 
0.01 0.8 B 152 0.793 160 0.854 168 0.776 
  C 900 0.776 308 0.846 322 0.841 
0.01 0.9 B 194 0.895 204 0.926 212 0.889 
  C 1146 0.893 392 0.931 408 0.940 
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Table 5 Statistical results of the above tests for the two examples 
Index 
Example1 
（τ =41.8 months） 
 Example2 
（τ =15.3 years） 
 
No 
(95%CI) 
Yes 
(95%CI) 
Difference/Ratio∮
(95%CI) P (statistic) 
No radiotherapy 
(95%CI) 
Radiotherapy
(95%CI) 
Difference/Ratio∮
(95%CI) P (statistics) 
CHR   0.86 
(0.59,1.25) 
0.053(1.93)a   1.14 
(0.78,1.65) 
0.503(0.67)a 
SHR   0.60 
(0.36,1.00) 
0.049(3.89)b   1.45 
(0.98,2.14) 
0.072(3.24)b 
RMSTc 19.72 21.55 1.83 0.601(0.52)c 8.52 9.09 0.66 0.510(0.66)c 
 (18.40,21.03) (14.82,28.28) (-5.03,8.69)  (8.46,8.57) (7.39,10.79) (-1.13,2.28)  
RMTL 15.49 
(13.53,17.45) 
9.57 
(5.18,13.96)
-5.92 
(-10.72, 1.11) 
0.016(2.41)d 2.96 4.68 1.72 0.014(2.46)d 
 0.004(3.06)e (2.69,3.24) (3.34,6.03) (0.35,3.09) 0.005(3.01)e 
∮: CHR and SHR are related to CSH and SDH ratio, respectively; RMSTc and RMTL are related to RMSTc difference and RMTL difference, respectively. 
a : log-rank; b : Gray; c : RMSTc; d : Diff; e : sDiff. 
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Figure 1. Six scenarios in the simulation study — CIF curves for the event of interest. 
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Figure 2. CIF curves and calculated sample size for the two examples. A) displays the 
CIF curves of death from treatment-related causes in example 1. B) displays the 
calculated sample size change with τ  in example 1. C) displays the CIF curves for 
death from LL in example 2. D) displays the calculated sample size change with τ  in 
example 2. 
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